Compare Abeona Therapeutics Inc (ABEO) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $119.02. Which is the better fit depends on your goals.
| ABEO | QQQE | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $122.72 |
52-Week Low | $4.17 | $96.06 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
QQQE trades at $120.89, up 0.62% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap-weighted peers. Recent news highlights its appeal for diversified growth exposure amid SpaceX's upcoming Nasdaq-100 inclusion (Zacks Investment Research, 2026-06-29).
Outlook remains positive due to defensive positioning and reduced mega-cap reliance, though macroeconomic headwinds and market volatility pose risks. The equal-weight strategy may offer better risk-adjusted returns in a flat or correcting market regime, as noted by analysts (Seeking Alpha, 2026-04-13).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
